What's Behind Boston Scientific's Optimism for Urology Growth?

Core Insights - Boston Scientific (BSX) reported strong sales growth in its Urology franchise, with a 27% operational increase and a 5% organic growth in Q3 2025, driven by international performance and the global Stone Management franchise [1][8] - The integration of Axonics is crucial for Boston Scientific, enhancing its presence in sacral neuromodulation (SNM), a high-growth area for the Urology business, although performance has been below expectations due to commercial disruptions [2][3] - The company received approval for the Axonics F15 in Europe, which, along with a series of innovations, is expected to bolster Urology growth in the upcoming year [3][8] Company Performance - Boston Scientific's Urology sales growth was primarily attributed to strong international gains and the global Stone Management franchise [1][8] - The company is trading at a forward five-year Price-to-Sales (P/S) ratio of 6.76X, significantly higher than the industry average of 2.95X [9] Earnings Estimates - Current earnings estimates for Boston Scientific indicate a projected EPS of 0.78 for the current quarter and 3.03 for the current year [11]